Ischemic postconditioning attenuate reperfusion injury of small intestine: impact of mitochondrial permeability transition

Transplantation. 2013 Feb 27;95(4):559-65. doi: 10.1097/TP.0b013e31827e6b02.

Abstract

Background: Ischemic postconditioning (IPoC) modulates the reperfusion maneuver to mitigate ischemia-reperfusion (I/R) injury. This study aims to investigate the effects and protective mechanism of IPoC on intestinal I/R injury.

Methods: Intestinal I/R was induced by occluding the superior mesenteric artery for 30 min followed by reperfusion for 60 min on male Wistar rats. IPoC was elicited by three cycles of 30-sec reperfusion and reocclusion of superior mesenteric artery at the initiation of reperfusion. Carboxyatractyloside (CATR), a mitochondrial permeability transition pore (mPTP) opener, and N-methyl-4-isoleucine cyclosporine (NIM811), an mPTP inhibitor, were administered separately in selected groups. The serum and intestinal sections were collected for analysis.

Results: IPoC and the administration of NIM811 significantly diminished the expression of intestinal-type fatty acid-binding protein and lactate dehydrogenase (3427±236.8 U/L for I/R, 1190.5±36.7 U/L for IPoC, 1399.3±295.6 U/L for I/R+NIM811, and 2002±370.9 IU/L for IPoC+CATR) in portal blood, the release of cytosolic cytochrome c, and the cleaved caspase 9 expression in intestinal mucosa after intestinal I/R injury (P<0.05). Histopathologically, IPoC and NIM811 mitigated mucosal damage after I/R as well (Chiu's score, 3.8±0.4 for I/R, 0.2±0.2 for IPoC, 0.4±0.2 for I/R+NIM811, and 4.2±0.2 for IPoC+CATR; apoptotic index, 59.5%±4.6% for I/R, 15.7%±15.7% for I/R+IPoC, 3.5%±3.5% for I/R+NIM811, and 67.1%±9.3% in IPoC+CATR). CATR negated the protection conferred by IPoC.

Conclusions: IPoC and NIM811 attenuate intestinal I/R injury. The addition of CATR negated the effects of IPoC, indicating that the protective mechanism of IPoC was associated with the modulation of mPTP opening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Atractyloside / analogs & derivatives
  • Atractyloside / pharmacology
  • Caspase 3 / metabolism
  • Cyclosporine / pharmacology
  • Cytochromes c / metabolism
  • Disease Models, Animal
  • Enzyme Activation
  • Fatty Acid-Binding Proteins / blood
  • Intestinal Mucosa / metabolism
  • Intestinal Mucosa / pathology
  • Intestine, Small / blood supply*
  • Intestine, Small / drug effects
  • Intestine, Small / metabolism*
  • Intestine, Small / pathology
  • Ischemic Postconditioning / methods*
  • L-Lactate Dehydrogenase / blood
  • Ligation
  • Male
  • Malondialdehyde / metabolism
  • Mesenteric Artery, Superior / surgery
  • Mesenteric Vascular Occlusion / metabolism
  • Mesenteric Vascular Occlusion / pathology
  • Mesenteric Vascular Occlusion / therapy*
  • Mitochondrial Membrane Transport Proteins / drug effects
  • Mitochondrial Membrane Transport Proteins / metabolism*
  • Mitochondrial Permeability Transition Pore
  • Oxidative Stress
  • Rats
  • Rats, Wistar
  • Reperfusion Injury / metabolism
  • Reperfusion Injury / pathology
  • Reperfusion Injury / prevention & control*
  • Time Factors

Substances

  • Fabp2 protein, rat
  • Fatty Acid-Binding Proteins
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • Atractyloside
  • Malondialdehyde
  • Cyclosporine
  • Cytochromes c
  • (melle-4)cyclosporin
  • L-Lactate Dehydrogenase
  • Casp3 protein, rat
  • Caspase 3
  • carboxyatractyloside